Hadean Ventures
Hadean Ventures is a life science investment firm based in Oslo, Norway, focused on the healthcare sector across Europe, particularly in the Nordic region. Founded in 2014, the firm manages a venture capital fund, Hadean Capital II, which was launched in 2021. Hadean Ventures invests in a variety of life science companies, including those in pharmaceuticals, biotechnology, and digital health. The firm is supported by a network of prominent private and institutional investors and has established collaborations with leading academic institutions and startup hubs throughout the region. With offices in Oslo and Stockholm, Hadean Ventures aims to foster innovation and growth in the life sciences sector.
Oncoinvent AS develops antibody based therapeutics for cancer patients. It offers Radspherin, an alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities; radiotherapeuti; radioimmunotherapeutic; and immunotherapeutic products. The company was founded in 2010 and is based in Oslo, Norway.
CardioMech AS is a Norwegian company specializing in the development of catheter-based systems for mitral valve repair. Founded in 2015 and headquartered in Trondheim, the company offers a transcatheter alternative to traditional cardiac surgery, focusing on the placement of artificial chords for the mitral valve. This innovative technology aims to provide new therapeutic options for patients suffering from severe, symptomatic degenerative mitral regurgitation, particularly those experiencing issues such as prolapse or flail. By enabling less invasive procedures, CardioMech seeks to improve treatment outcomes for individuals with structural heart diseases.
Oncoinvent AS develops antibody based therapeutics for cancer patients. It offers Radspherin, an alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities; radiotherapeuti; radioimmunotherapeutic; and immunotherapeutic products. The company was founded in 2010 and is based in Oslo, Norway.
Nisonic is a medical technology company that develops products that will allow physicians to diagnose and monitor increased intracranial pressure (ICP) in an easier and cost-effective way. Nisonic will offer an accurate non-invasive ICP monitoring system for emergency departments, EMC, intensive care and critical care units. Early detection of ICP and intervention are critical to lowering death and disability rates, but currently only invasive methods are available to monitor increased ICP. Invasive methods are associated with risk of bleeding and infections, are only available at larger hospitals and have a considerable cost. While invasive intracranial pressure monitoring has been available for many years, non-invasive measurement has so far not been accurate enough. Nisonic is developing an software that analyzes ultrasound images of the eye to monitor increased ICP, and that can be integrated into ultrasound devices on the market, enabling widespread use among physicians and other health workers.